A.M. Vitals: FDA Advisory Panel Votes Against Drugs as Prostate-Cancer Preventatives

Published On: December 3rd, 2010

Also: food-safety bill hits a snag; Allergan seeks broader (though thinner) audience for Lap-Band; PhRMA dollars; Merck bets on experimental insulin product.

See the original post:
A.M. Vitals: FDA Advisory Panel Votes Against Drugs as Prostate-Cancer Preventatives

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

Did you know:

Lung cancer kills more African Americans and American Indians/Alaska Natives than any other type of cancer

A.M. Vitals: FDA Advisory Panel Votes Against Novartis’s Gout Drug
Drug Vote: An FDA advisory panel voted not to recommend approval of Novartis’s Ilaris for gout pain, though it did say the drug is effective, the WSJ reports . ..
A.M. Vitals: FDA Panel Votes Against Diabetes Drug From Bristol, Astra
Drug Vote: An FDA advisory panel voted 9-6 against approving dapagliflozin, a new type of diabetes drug from Bristol-Myers Squibb and AstraZeneca, saying more information is needed on possible risks including breast and bladder cancers, the WSJ reports . Some panel members, however, said teasing out those possible safety problems would be best accomplished not..
A.M. Vitals: FDA Advisory Panel Approves Wider Use of Lilly’s Cymbalta
Also: Low demand so far for high-risk pools; egg recall; “junk” DNA linked to disease. ..
A.M. Vitals: FDA Advisory Panel Backs Lower Dose of Novartis Lung Drug
Lung-Drug Recommendation: An FDA advisory panel backed the approval of a 75-microgram dose of Novartis’s drug for chronic obstructive pulmonary disease, indacaterol, but not the higher dose of the drug used in Europe, the WSJ reports . That’s significant because Novartis is developing another lung drug that contains a dose of indacaterol that’s higher than..
FDA Panel Votes Against Arena’s Weight-Loss Drug Lorcaserin
On the key question of whether the benefits of the drug outweigh the risks, 5 committee members voted yes and 9 voted no. ..
A.M. Vitals: FDA Panel Votes to Strip Avastin’s Breast Cancer Indication
Also: Harvard Med School tightens its rules on faculty-industry involvement; WellPoint exec leaves; Chamber of Commerce sets up health-overhaul complaint site. ..

Orshe